Eli Lilly and Company (LLY) vs Merck & Co., Inc. (MRK)
See how Eli Lilly and Company and Merck & Co., Inc. differ across market data and performance, so you can decide which asset best fits your strategy.
$1,179.27
NYSE
Eli Lilly & Co. is a pharmaceutical company focused on neuroscience, cardiometabolic disease, oncology, and immunology. Its leading products include Verzenio and Jaypirca in cancer treatment; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin in cardiometabolic care; and Taltz and Olumiant in immunology.
View Full Page$145.6
NYSE
Merck & Co., Inc. develops pharmaceutical products across multiple therapeutic areas, including cardiometabolic disorders, oncology, and infectious diseases. In cancer treatment, its immuno-oncology portfolio, led by Keytruda, represents a significant driver of total revenue. The company also maintains a strong vaccines business focused on preventing pediatric illnesses, alongside Gardasil for human papillomavirus. In addition, Merck markets animal health products. Geographically, 47% of the company’s sales come from its U.S. human health segment, which includes pharmaceuticals and vaccines.
View Full PageKey Metrics Comparison
Eli Lilly and CompanyLLY
Market Cap$1.051T
Price$1,179.27
24h Change+0.83%
24h Volume$1.38M
Employees50,000
Shares Outstanding944,818,881
Merck & Co., Inc.MRK
Market Cap$359.22B
Price$145.6
24h Change+2.26%
24h Volume$8M
Employees73,000
Shares Outstanding2,469,879,206
Category Performance
Visual comparison across key categories. Ring fill represents relative strength or share between the two assets.
Market Share
Share of combined market cap
LLY
74.5%MRK
25.5%Volume Share
Share of combined 24h volume
LLY
14.8%MRK
85.2%24h Performance
Price change over last 24 hours
LLY
0.83%MRK
2.26%Price Comparison
Eli Lilly and Company
Merck & Co., Inc.